The Uromigos

GU Oncology Now

During the second-annual Uromigos Live &amp; Unplugged event, Thomas Powles, MBBS, MRCP, MD; Brian Rini, MD, FASCO; Toni Choueiri, MD; Sumanta Pal, MD, FASCO; and Tian Zhang, MD, highlight a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2, as well as their thoughts on the current role of IO-based therapy after prior IO.Then, the panel move into a discussion of belzutifan and predict the results of this novel agent plus TKI in IO-refractory disease.View the <a href="https://guoncologynow.com/post/uromigos-live-2023-frontline-metastatic-renal-cancer-time-for-reflection" target="_blank" rel="noopener">second kidney cancer session</a> of the day on frontline metastatic disease.

Uromigos Live 2023: Management of IO-Refractory RCC

Uromigos Live 2023

The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe